
Dupixent CTCL Lawsuits: The Next Emerging MDL
Plaintiffs are moving to centralize Dupixent cutaneous T-cell lymphoma cases as an MDL after the FDA flagged a safety signal.
7 articles with this tag

Plaintiffs are moving to centralize Dupixent cutaneous T-cell lymphoma cases as an MDL after the FDA flagged a safety signal.


The first formula-linked infant botulism outbreak (48 cases across 19 states) is now a federal MDL in New York.

There is no official average payout in the Bard hernia mesh settlement. BD's $1B+ deal covers 38,000+ suits, and medical records drive each claim's value.



Camp Lejeune litigation updates including court rulings, settlement progress, and how law firms are addressing medical records with nearly 500,000 claims filed.